Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.51 |
| ▸ | CDC7 | O00311 | 4/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.51 |
| ▸ | PIM1 | P11309 | 3/20 | 0.51 |
| ▸ | PRKACA | P17612 | 3/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.49 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.49 |
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.49 |
| ▸ | PAK4 | O96013 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857290 | 0.89 | CDC7 (0.64) | DYRK1ACLK4CDC7MAP4K4PIM1 | |
| SCHEMBL17165387 | 0.81 | CDC7 (0.54) | DYRK1ACLK4CDC7MAP4K4PIM1 | |
| SCHEMBL857665 | 0.78 | CDC7 (0.68) | DYRK1ACLK4CDC7MAP4K4PIM1 | |
| SCHEMBL15637831 | 0.77 | CA12 (0.45) | DYRK1ACLK4MAP4K4PIM1PRKACA | |
| SCHEMBL17895432 | 0.76 | CDC7 (0.69) | DYRK1ACLK4CDC7MAP4K4PIM1 | |
| SCHEMBL29484276 | 0.76 | CDC7 (0.69) | DYRK1ACLK4CDC7MAP4K4PIM1 | |
| SCHEMBL15638024 | 0.76 | TGFBR1 (0.46) | DYRK1ACLK4MAP4K4PIM1PRKACA | |
| SCHEMBL28891614 | 0.76 | DAPK3 (0.46) | DYRK1ACLK4MAP4K4PIM1PRKACA | |
| SCHEMBL28421012 | 0.76 | CYP2A6 (0.53) | TGFBR1TDO2 | |
| SCHEMBL21317946 | 0.75 | GSK3B (0.37) | DYRK1ACLK4MAP4K4PIM1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| CN-106536507-B | 2, 3-disubstituted pyridine compounds as TGF- β inhibitors and methods of use thereof | 里格尔药品股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| EP-3129367-B1 | 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3129367-B1 | 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | MIDCAP FINANCIAL TRUST | 2017-04-06 | — | — | US | disclosed |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | MIDCAP FINANCIAL TRUST | 2017-04-06 | — | — | US | disclosed |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | MIDCAP FINANCIAL TRUST | 2017-04-06 | — | — | US | disclosed |
| EP-3129367-A1 | 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE | Rigel Pharmaceuticals, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015157093-A1 | 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015157093-A1 | 2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | DYRK1A 3406/4885CLK4 3205/4885CDC7 811/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | DYRK1A 2300/4885CLK4 3110/4885CDC7 736/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | DYRK1A 2482/4885CLK4 3162/4885CDC7 742/4885 |
| US-20170096409-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR1, TGFBR2, ACVR1 | DYRK1A 3406/4885CLK4 3205/4885CDC7 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.